Biotech company Regeneron (NASDAQ: REGN) will be reporting earnings this Friday before market open. Here’s what investors should know.
Regeneron missed analysts’ revenue expectations by 6.1% last quarter, reporting revenues of $3.03 billion, down 3.7% year on year. It was a disappointing quarter for the company, with a miss of analysts’ EPS estimates.
Is Regeneron a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Regeneron’s revenue to decline 6.9% year on year to $3.30 billion, a reversal from the 12.3% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $8.43 per share.
Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 13 downward revisions over the last 30 days (we track 14 analysts). Regeneron has missed Wall Street’s revenue estimates twice over the last two years.
Looking at Regeneron’s peers in the biotechnology segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Incyte delivered year-on-year revenue growth of 16.5%, beating analysts’ expectations by 5.5%, and United Therapeutics reported revenues up 11.7%, falling short of estimates by 0.5%. Incyte traded up 10.5% following the results.
Read our full analysis of Incyte’s results here and United Therapeutics’s results here.
The euphoria surrounding Trump’s November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the biotechnology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.9% on average over the last month. Regeneron is up 3% during the same time and is heading into earnings with an average analyst price target of $721.52 (compared to the current share price of $550.97).
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
